Ureteral stents coated with quorum sensing inhibitor RIP were implanted in rats bladder and shown to suppress Staphylococcus aureus on the stent and in urine and was especially effective when combined with teicoplanin. Coating ureteral stents with RIP thus increases the efficacy of teicoplanin in preventing ureteral stent-associated staphylococcal infections.
Adult female Wistar rats (weight range 180 to 250 g) (n=5) were used. Study included a control group (C 0 ) without bacterial challenge to evaluate the sterility of the surgical procedure, a challenged control group (C 1 ) without antibiotic prophylaxis, and three challenged groups that received a) 10 mg/kg teicoplanin intraperitoneally, immediately after stent implantation, b) RIPcoated stents where 0.2-cm 2 sterile stents (Biosoft®Duo, Porges-Mentor, France) were incubated in 1 mg/L RIP (Neosystem) solution for 30 min immediately before implantation; and c) intraperitoneal teicoplanin (Aventis) plus RIP-coated stent at the above concentrations. Experiments were performed in duplicate. The dosage of teicoplanin resembled that usually used in the human clinical setting while RIP dosage was chosen on the basis of previous reports (1, 2) . For statistical analysis, the data were pooled and referred to all 10 animals from each pair of groups.
The rats were anesthetized by an intramuscular injection of ketamine and xylazine (30 mg/kg and 8 mg/kg respectively), the hair was shaved and the skin cleansed with a 10% povidoneiodine solution. The bladder was exposed through a suprapubic incision and opened at the dome (7).
After cystotomy, stents were inserted into the bladder. Before implantation, some of the ureteral stent segments were impregnated with RIP as described above. The bladder was sutured with 000 surgical silk. After the surgical intervention, a saline solution (1 ml) containing 2×10 7 CFU/ml S. aureus (SD) (4,19) was inoculated into the bladder using a tuberculin syringe. Some of the animals received teicoplanin intraperitoneally, immediately after stent implantation. The animals were returned to individual cages and thoroughly examined daily. Twenty-four hours after stent placement, urine cultures were performed through a transvesical sample taken by an insulin syringe, to verify the sterility or infection. Stents were explanted at day 5 following implantation.
Enumeration of viable bacteria was performed by culturing serial 10-fold dilutions (0.1 ml) of the bacterial suspension on blood agar plates. All plates were incubated at 37°C for 48 h. The organisms were quantitated by counting the number of CFU per plate (1). The limit of detection was approximately 10 CFU/ml. Culture results were presented as mean ± S.D. of the mean and statistical comparisons between groups were made using analysis of variance (ANOVA) on the log- ± 0.8×10 3 CFU/ml. Animals that had RIP-coated stents showed bacterial counts of 6.7×10 4 ± 1.4×10 3 (P<0.05). Animals that had RIP-coated stents and treated with teicoplanin had no bacterial counts (P<0.001), indicating that RIP combined with teicoplanin showed efficacies higher than that of each single compound alone. Urine cultures confirmed these microbiological data and were negative both for the uncontaminated group and for the combined treatment group. For the singly treated groups they were positive with a bacterial count of 10 4 CFU/ml both for RIP-and for teicoplanin-treated group (Table 1) . None of the animals included in any group died or had any clinical evidence of drug-related adverse effects.
A C C E P T E D
Data presented here shows that the use of RIP-impregnated stent with or without combination with conventional antibiotics caused significantly lowered bacterial loads. Similarly to teicoplanin, RIP caused a significant reduction in bacterial load on the ureteral stent tissue when compared with control untreated animals and when teicoplanin and RIP were combined, no evidence of bacteria was detected on the stent or in the urine. In summary, not only did RIP by itself reduce bacterial load, it also enhanced the effect of teicoplanin. Our data showed the presence of large errors for bacteriological counts in each of the treated animal group. We cannot affirm that some bladders have been cured and others not: in the clinical setting the positivity of an urine 

